Article Text

This article has a correction. Please see:

PDF

Chronic obstructive pulmonary disease: organisation of care

Statistics from Altmetric.com

S12 BENCHMARKING CHRONIC OBSTRUCTIVE PULMONARY DISEASE ACROSS AN INNER CITY PRIMARY CARE TRUST: ONE YEAR ON

JA Roberts. Salford PCT, Salford, UK

Background: Our integrated chronic obstructive pulmonary disease (COPD) team works closely with general practice to improve COPD care in a primary care trust (PCT) with high levels of social deprivation and COPD. Integral to our approach is the general practice COPD register that uses a standardised template to structure consultations in line with national guidelines. De-identified data are collected remotely at 3-month intervals.

Aims: To compare data from baseline with those available at 12 months. To establish general practice adherence to guideline recommendations on COPD follow-up and management.

Methods: We retrospectively analysed data from the COPD register at 12 months and compared with baseline COPD prevalence, FEV1 percentage predicted, MRC score, smoking status and current medication.

Results: 12-month data were available from 25 of 56 practices (55% of the total population and 56% of the COPD population). Recorded diagnosis of COPD n  =  3291 (n  =  2888 baseline). Mean prevalence 2.4% (range 1.3–4.5%; 2.1% baseline). 53% female. Mean age 68.7 years (range 30–97). Smoking status at 12 months (baseline), never smoked 12% (12%), ex-smoker 48% (46%), current smoker 40% (42%). 48% of patients (n  =  1574) had a read code for COPD review in the last 12 months (range 0–83%). 54% (n  =  1781) of patients had undergone spirometry in the last 12 months. Severity of COPD could not be ascertained from 51 of these readings. 12% had FEV1 greater than 80% (10% baseline), 53% mild COPD (44% baseline), 27% moderate COPD (30.5% baseline), 8% severe COPD (10% baseline) according to NICE guidelines (2004). MRC score was recorded on 48% of patients (27% at baseline). The table highlights the proportion of patients receiving drug treatment category according to severity for total COPD population at 12 months (baseline).

Conclusions: In the 12 months …

View Full Text

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Linked Articles

  • Correction
    BMJ Publishing Group Ltd and British Thoracic Society